TCR therapy - Pipeline Insight, 2021
This report can be delivered to the clients within 3-5 business days
DelveInsight’s, “TCR therapy – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 35+ pipeline drugs in TCR therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TCR therapy: Overview
T-cell receptor (TCR)-based adoptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process that involves patient screening (e.g., for HLA-A*02:01 and specific tumor targets), leukapheresis, generation of transduced TCR product, lymphodepletion, and infusion of the TCR-based adoptive therapy. The majority of TCR structures are heterodimers comprised of ?- and ?-chains that are covalently linked via a disulfide bond between the conserved cysteine residues located within the constant region of each chain. Adoptive cell therapy (ACT), which uses genetically engineered human lymphocytes, is increasingly being investigated in patients with hematologic malignancies and solid tumors. The implementation of TCR therapy will require a shortened time to manufacture TCR products and decreased overall cost associated with the administration of TCR therapy.
'TCR therapy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR therapy pipeline landscape is provided which includes the disease overview and TCR therapy treatment guidelines. The assessment part of the report embraces, in depth TCR therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the TCR therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TCR therapy Emerging Drugs
Further product details are provided in the report……..
TCR therapy: Therapeutic Assessment
This segment of the report provides insights about the different TCR therapy drugs segregated based on following parameters that define the scope of the report, such as:
TCR therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TCR therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TCR therapy drugs.
TCR therapy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “TCR therapy – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 35+ pipeline drugs in TCR therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TCR therapy: Overview
T-cell receptor (TCR)-based adoptive therapy employs genetically modified lymphocytes that are directed against specific tumor markers. This therapeutic modality requires a structured and integrated process that involves patient screening (e.g., for HLA-A*02:01 and specific tumor targets), leukapheresis, generation of transduced TCR product, lymphodepletion, and infusion of the TCR-based adoptive therapy. The majority of TCR structures are heterodimers comprised of ?- and ?-chains that are covalently linked via a disulfide bond between the conserved cysteine residues located within the constant region of each chain. Adoptive cell therapy (ACT), which uses genetically engineered human lymphocytes, is increasingly being investigated in patients with hematologic malignancies and solid tumors. The implementation of TCR therapy will require a shortened time to manufacture TCR products and decreased overall cost associated with the administration of TCR therapy.
'TCR therapy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the TCR therapy pipeline landscape is provided which includes the disease overview and TCR therapy treatment guidelines. The assessment part of the report embraces, in depth TCR therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, TCR therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TCR therapy R&D. The therapies under development are focused on novel approaches to treat/improve TCR therapy.
This segment of the TCR therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TCR therapy Emerging Drugs
- GSK3377794: GlaxoSmithKline
- BPX-701: Bellicum Pharmaceuticals
- MDG1011: Medigene AG
Further product details are provided in the report……..
TCR therapy: Therapeutic Assessment
This segment of the report provides insights about the different TCR therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in TCR therapy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
TCR therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TCR therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TCR therapy drugs.
TCR therapy Report Insights
- TCR therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing TCR therapy drugs?
- How many TCR therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TCR therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TCR therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TCR therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
TCR therapy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
Comparative Analysis
GSK3377794: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
BPX-701: Bellicum Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
MCC1 TCR: Bluebird Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
TCR therapy Key Companies
TCR therapy Key Products
TCR therapy- Unmet Needs
TCR therapy- Market Drivers and Barriers
TCR therapy- Future Perspectives and Conclusion
TCR therapy Analyst Views
TCR therapy Key Companies
Appendix
Executive Summary
TCR therapy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
Comparative Analysis
GSK3377794: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
BPX-701: Bellicum Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
MCC1 TCR: Bluebird Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
TCR therapy Key Companies
TCR therapy Key Products
TCR therapy- Unmet Needs
TCR therapy- Market Drivers and Barriers
TCR therapy- Future Perspectives and Conclusion
TCR therapy Analyst Views
TCR therapy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for TCR therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for TCR therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for TCR therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for TCR therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
